内容紹介
Induction of Allergic Reactions by Anticancer Drugs in Outpatient Chemotherapy
Summary
We must understand the conditions during the onset of allergic reactions induced by anticancer drugs in order to respond with an appropriate treatment. We have therefore conducted this study, focusing on allergic reactions induced by each anticancer drug used in outpatient chemotherapy. Allergic reactions occurred in a total of 3.9%(76 cases), most of which were induced by platinum and taxane anticancer drugs. The number of administrations at symptom onset and the times of onset for platinums and taxanes were 11.7±1.3 times and 43.3±4.8 minutes for platinum; and 2.3±0.5 times and 18.1±3.6 minutes for taxanes, respectively. This demonstrated a significant difference between these two drugs(both were p<0.01). In terms of re-administration following the onset of allergic reactions, 21 cases(72.4%)out of 29 cases(38.2%)were able to continue the administration of suspected drugs. We studied various factors surrounding the possibility of continued administration to two groups which were or were not able to continue receiving treatment. No significant differences were observed between the groups. For continuous safe treatment, it is necessary to understand the characteristics of allergic reactions induced by each anticancer drug. It is also advisable to consider possible precautions(by introducing prevention regimens)and appropriate measures at the time of re-administration, following the onset of allergic reactions.
要旨
抗がん剤によるアレルギー症状においては,適切な対応ができるようにアレルギー症状発現状況を把握する必要がある。そこで,外来化学療法において各抗がん剤のアレルギー症状発現について検討した。アレルギー症状発現率は全体で3.9%(76件)であり,プラチナ系およびタキサン系抗がん剤が多くを占めた。プラチナ系抗がん剤とタキサン系抗がん剤のアレルギー症状発現時の投与回数および発現時間は,それぞれ11.7±1.3回:2.3±0.5回および43.3±4.8分:18.1±3.6分であり,両系統別薬剤において有意な差が認められた(いずれもp<0.01)。また,アレルギー症状発現後の再投与の継続性については,29件(38.2%)中21件(72.4%)が継続投与可能であった。再投与の継続性について継続投与不可群と投与可群に分け各種要因の影響を検討したが,いずれにおいても有意な差は認められなかった。安全に治療を継続するためにも各抗がん剤のアレルギー症状の特徴を把握し,予防策(予防レジメンの導入)やアレルギー症状発現後における再投与時の適切な対策を検討していく必要があると思われる。
目次
Summary
We must understand the conditions during the onset of allergic reactions induced by anticancer drugs in order to respond with an appropriate treatment. We have therefore conducted this study, focusing on allergic reactions induced by each anticancer drug used in outpatient chemotherapy. Allergic reactions occurred in a total of 3.9%(76 cases), most of which were induced by platinum and taxane anticancer drugs. The number of administrations at symptom onset and the times of onset for platinums and taxanes were 11.7±1.3 times and 43.3±4.8 minutes for platinum; and 2.3±0.5 times and 18.1±3.6 minutes for taxanes, respectively. This demonstrated a significant difference between these two drugs(both were p<0.01). In terms of re-administration following the onset of allergic reactions, 21 cases(72.4%)out of 29 cases(38.2%)were able to continue the administration of suspected drugs. We studied various factors surrounding the possibility of continued administration to two groups which were or were not able to continue receiving treatment. No significant differences were observed between the groups. For continuous safe treatment, it is necessary to understand the characteristics of allergic reactions induced by each anticancer drug. It is also advisable to consider possible precautions(by introducing prevention regimens)and appropriate measures at the time of re-administration, following the onset of allergic reactions.
要旨
抗がん剤によるアレルギー症状においては,適切な対応ができるようにアレルギー症状発現状況を把握する必要がある。そこで,外来化学療法において各抗がん剤のアレルギー症状発現について検討した。アレルギー症状発現率は全体で3.9%(76件)であり,プラチナ系およびタキサン系抗がん剤が多くを占めた。プラチナ系抗がん剤とタキサン系抗がん剤のアレルギー症状発現時の投与回数および発現時間は,それぞれ11.7±1.3回:2.3±0.5回および43.3±4.8分:18.1±3.6分であり,両系統別薬剤において有意な差が認められた(いずれもp<0.01)。また,アレルギー症状発現後の再投与の継続性については,29件(38.2%)中21件(72.4%)が継続投与可能であった。再投与の継続性について継続投与不可群と投与可群に分け各種要因の影響を検討したが,いずれにおいても有意な差は認められなかった。安全に治療を継続するためにも各抗がん剤のアレルギー症状の特徴を把握し,予防策(予防レジメンの導入)やアレルギー症状発現後における再投与時の適切な対策を検討していく必要があると思われる。